Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;198(1):73-81.
doi: 10.1111/bjh.18166. Epub 2022 Apr 1.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma

Ewa Paszkiewicz-Kozik  1 , Wojciech Michalski  1 , Michał Taszner  2 , Monika Mordak-Domagała  3 , Joanna Romejko-Jarosińska  1 , Wanda Knopińska-Posłuszny  4   5 , Jacek Najda  6 , Anna Borawska  1 , Monika Chełstowska  7 , Monika Świerkowska  1 , Anna Dąbrowska-Iwanicka  1 , Agata Malenda  7 , Agnieszka Druzd-Sitek  1 , Robert Konecki  1 , Beata Kumiega  8 , Michał Osowiecki  1 , Beata Ostrowska  1 , Tomasz Szpila  7 , Marcin Szymański  1 , Łukasz Targoński  1 , Katarzyna Domańska-Czyż  1 , Lidia Popławska  1 , Sebastian Giebel  6 , Andrzej Lange  3 , Andrzej Pluta  9 , Jan Maciej Zaucha  2   4 , Grzegorz Rymkiewicz  1 , Jan Walewski  1
Affiliations

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma

Ewa Paszkiewicz-Kozik et al. Br J Haematol. 2022 Jul.

Abstract

The efficacy of salvage treatment of diffuse large B-cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety of ofatumumab with iphosphamide, etoposide and cytarabine (O-IVAC) was evaluated in a single-arm study. Dosing was modified for elderly patients. Patients received up to six cycles of treatment. The primary end-point was the overall response rate (ORR). Patients were evaluated every two cycles and then six and 12 months after treatment. Other end-points included progression-free survival (PFS), event-free survival (EFS), overall survival (OS) and safety. Seventy-seven patients received salvage treatment with O-IVAC. The average age was 56.8 years; 39% had an Eastern Cooperative Oncology Group (ECOG) performance status of at least 3; 78% had disease of Ann Arbor stage 3 or 4; 58% received one or more prior salvage therapies. The ORR for O-IVAC was 54.5%. The median duration of study follow-up was 70 months. The median PFS and EFS were 16.3 months each. The median OS was 22.7 months. Age, ECOG performance status and the number of prior therapy lines were independent predictors of survival. Treatment-related mortality was 15.5%. O-IVAC showed a high response rate in a difficult-to-treat population and is an attractive treatment to bridge to potentially curative therapies.

Keywords: IVAC protocol; ofatumumab; refractory and relapsed diffuse large B-cell lymphoma; salvage treatment.

PubMed Disclaimer

Conflict of interest statement

Anna Borawska, Andrzej Lange, Agata Malenda,Beata Kumiega, Beata Ostrowska, Grzegorz Rymkiewicz, Jacek Najda, Katarzyna Domańska‐Czyż, Lidia Popławska, Łukasz Targoński, Monika Chełstowska, Michał Osowiecki, Monika Mordak‐Domagała, Monika Świerkowska, Marcin Szymański, Robert Konecki, Tomasz Szpila, Wanda Knopińska‐Posłuszny and Wojciech Michalski have no conflict of interests to declare. Agnieszka Druzd‐Sitek received lecture honoraria from Amgen, Takeda and Celgene‐BMS. Sebastian Giebel received lecture and consulting fees from Gilead, Novartis, Roche and Servier. Andrzej Pluta received consulting fees from Kedrion Pharma. Ewa Paszkiewicz‐Kozik received lecture fees from Roche, Takeda, Abbvie and travel grants from Roche. Jan Maciej Zaucha received consulting fees from Abbvie, Takeda, Roche, Amgen, BMS, Gilead, speaker fees from Novartis, Takeda, Abbvie, Janssen and travel grants from Roche and Gilead. Joanna Romejko‐Jarosińska received lecture honoraria from Roche, Takeda, Abbvie, Gilead and Servier. Jan Walewski received consulting fees from Roche, Takeda, Abbvie, Novartis and Gilead, research funding from Roche and GSK/Novartis and lecture honoraria from Roche, Takeda, Janssen‐Cilag, Servier, Abbvie, Amgen, Novartis and Gilead. Michał Taszner received lecture honoraria from Takeda, Roche and Celgene and travel grants from Novartis.

Figures

FIGURE 1
FIGURE 1
Progression‐free survival (A), event‐free survival (B) and overall survival (C) in transplantation‐ineligible refractory and relapsed diffuse large B‐cell lymphoma treated with ofatumumab with etoposide, iphosphamide and cytarabine
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. - PMC - PubMed
    1. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP‐like chemotherapy with or without rituximab in young patients with good‐prognosis diffuse large‐B‐cell lymphoma: 6‐year results of an open‐label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22. - PubMed
    1. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long‐term outcome of patients in the LNH‐98.5 trial, the first randomized study comparing rituximab‐CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–5. - PMC - PubMed
    1. Feugier P, Van Hoof A, Sebban C, Solal‐Celigny P, Bouabdallah R, Fermé C, et al. Long‐term results of the R‐CHOP study in the treatment of elderly patients with diffuse large B‐cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–26. - PubMed
    1. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B‐cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90. - PMC - PubMed

Publication types